Q4 Earnings Estimate for Moderna Issued By Leerink Partnrs

Moderna, Inc. (NASDAQ:MRNA) – Research analysts at Leerink Partnrs issued their Q4 2025 EPS estimates for Moderna in a note issued to investors on Monday, January 13th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($2.54) per share for the quarter. The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share. Leerink Partnrs also issued estimates for Moderna’s FY2028 earnings at ($2.70) EPS and FY2029 earnings at ($0.07) EPS.

A number of other analysts have also recently commented on MRNA. Sanford C. Bernstein began coverage on shares of Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price on the stock. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Friday, November 8th. Jefferies Financial Group decreased their target price on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. JPMorgan Chase & Co. dropped their price target on Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 26th. Finally, Barclays reduced their price objective on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Four analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $75.58.

Moderna Price Performance

Shares of MRNA stock opened at $33.76 on Wednesday. The business’s fifty day moving average is $41.11 and its 200 day moving average is $67.32. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The stock has a market cap of $12.99 billion, a price-to-earnings ratio of -5.80 and a beta of 1.60. Moderna has a twelve month low of $31.94 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.39) EPS.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders sold 2,664 shares of company stock worth $115,210. 15.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna in the 2nd quarter worth $26,000. Plato Investment Management Ltd grew its holdings in Moderna by 230.4% during the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after purchasing an additional 288 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in Moderna in the second quarter worth about $75,000. Blue Trust Inc. raised its stake in shares of Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after buying an additional 574 shares during the period. Finally, Larson Financial Group LLC lifted its position in shares of Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after buying an additional 317 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.